Search Results for “immune” – Page 82 – media

the Mayo Clinic experience

Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and normal tissue. As such, their main toxicity is inducing immune-mediated tissue damage.
- Source: acrabstracts.org
- 492
- January 30, 2018
inhibitor malignancies Researches
Sanofi snaps up Ablynx for 3.9bn euros

Sanofi will launch public offers to acquire all shares, including ADSs, warrants and convertible bonds of Ablynx. News of the deal will no doubt come as a great disappointment to Novo Nordisk, which recently stepped up its efforts to buy Ablynx with a second offer valued at around 2.6 billion euros.
- Source: Currenthollywood
- 643
- January 30, 2018
Market Views Sanofi Ablynx
GSK’s Shingrix Gets Positive CHMP Opinion For Prevention Of Shingles

GlaxoSmithKline plc (GSK,GSK.L) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has issued a positive opinion recommending marketing authorisation for Shingrix (RELATED: CDC backs GSK’s Shingrix over Merck & Co’s Zostavax) for the prevention of shingles, or herpes zoster, and post-herpetic neuralgia or PHN
- Source: rttnews
- 604
- January 30, 2018
Company Insight herpes zoster PHN shingles Shingrix
Scotland’s Synpromics expands gene therapy work with UCL deal

Edinburgh, Scotland based Synpromics has teamed up with UCL Great Ormond Street Institute of Child Health to develop novel gene therapies for diseases affecting the haematopoietic system.
- Source: drugdu
- 500
- January 29, 2018
cell and gene therapy haematopoietic immune system novel gene-based medicines UCL
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the U.S.
- Source: finance.yahoo
- 532
- January 26, 2018
Gene therapy Market Views voretigene neparvovec
York County sues 25 opioid manufacturers, distributors

With opioid-overdose deaths skyrocketing as 2017 comes to a close, York County is suing more than two dozen drug companies that "have intentionally misled the public about the dangers of opioids."
- Source: Yorkdispatch
- 595
- January 25, 2018
opioid polices
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
- Source: Cnbc
- 982
- January 24, 2018
cancer CAR–T Market Views
Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.
- Source: Prnewswire
- 768
- January 22, 2018
biopharmaceutical EP4 antagonist Market Views
Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to advance public health measures.
- Source: medicalxpress
- 675
- January 22, 2018
smallpox synthetic DNA synthetic virus vaccine
The Top 8 Technologies Combating Food Allergy

Food allergy has been referred to as the second wave of the allergy epidemic, asthma being the first.
- Source: Medical Futurist
- 929
- January 22, 2018
Allergies Company Insight digital health healthcare technology mHealth

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.